Literature DB >> 15148095

Comparison of skin biopsy triage decisions in 49 patients with pigmented lesions and skin neoplasms: store-and-forward teledermatology vs face-to-face dermatology.

Michael Shapiro1, William D James, Rex Kessler, Francis C Lazorik, Kenneth A Katz, John Tam, David S Nieves, Jeffrey J Miller.   

Abstract

OBJECTIVE: To determine the relative efficacy of store-and-forward teledermatology vs face-to-face dermatology consultations in triage decisions about the need for a biopsy of neoplastic skin changes.
DESIGN: Prospective study of consecutive patients judged by an internist to require dermatologic consultation for a skin growth.
SETTING: Private primary care and dermatology practices and an academic dermatology practice. PATIENTS: Patients requiring dermatology consultation for evaluation of skin growths. Patients were seen by a single primary care physician between July 10, 1998, and August 4, 2000. INTERVENTION: Digital photographs of skin growths were obtained by the primary care physician and evaluated by a teledermatologist. The patient was then seen face-to-face by a dermatologist. A biopsy was performed if either dermatologist favored biopsy. MAIN OUTCOME MEASURES: Decisions to perform a biopsy. Agreement between the dermatologists was assessed.
RESULTS: Of the 49 patients with evaluable photographs, the face-to-face dermatologist and teledermatologist recommended a biopsy for the same 26 patients, yielding a sensitivity of the teledermatologist of 1.00 (95% confidence interval [CI], 0.87-1.00) and a specificity of 1.00 (95% CI, 0.85-1.00). The agreement between the dermatologists (kappa) was 1.00 (95% CI, 0.72-1.00).
CONCLUSION: Store-and-forward teledermatology may provide an accurate and cost-effective method of determining whether skin growths in patients presenting to primary care physicians should undergo biopsy.

Entities:  

Mesh:

Year:  2004        PMID: 15148095     DOI: 10.1001/archderm.140.5.525

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Utility of a Noninvasive 2-Gene Molecular Assay for Cutaneous Melanoma and Effect on the Decision to Biopsy.

Authors:  Laura K Ferris; Burkhard Jansen; Jonhan Ho; Klaus J Busam; Kenneth Gross; Doyle D Hansen; John P Alsobrook; Zuxu Yao; Gary L Peck; Pedram Gerami
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

2.  Sensitivity and Specificity of the Remote Evaluation of Therapeutic Response in Cutaneous Leishmaniasis Using Photographs from a Mobile Application.

Authors:  Alejandra Maria Del Castillo; Maria Del Mar Castro; Alexandra Cossio; Jonny Alejandro García Luna; Domiciano Rincón; Ruth Mabel Castillo; Miguel Darío Prieto; David Esteban Rebellón-Sánchez; Andrés Navarro; Neal Alexander
Journal:  Am J Trop Med Hyg       Date:  2022-07-25       Impact factor: 3.707

3.  Development of a teledermatopathology consultation system using virtual slides.

Authors:  Ikunori Nakayama; Tsubasa Matsumura; Akihisa Kamataki; Miwa Uzuki; Kenji Saito; James Hobbs; Toshihide Akasaka; Takashi Sawai
Journal:  Diagn Pathol       Date:  2012-12-13       Impact factor: 2.644

4.  Teledermatology for diagnosing skin cancer in adults.

Authors:  Naomi Chuchu; Jacqueline Dinnes; Yemisi Takwoingi; Rubeta N Matin; Susan E Bayliss; Clare Davenport; Jacqueline F Moreau; Oliver Bassett; Kathie Godfrey; Colette O'Sullivan; Fiona M Walter; Richard Motley; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2018-12-04

5.  Digital photography in skin cancer screening by mobile units in remote areas of Brazil.

Authors:  Carlos Eduardo Goulart Silveira; Thiago Buosi Silva; José Humberto Guerreiro Tavares Fregnani; René Aloisio da Costa Vieira; Raphael Luiz Haikel; Kari Syrjänen; André Lopes Carvalho; Edmundo Carvalho Mauad
Journal:  BMC Dermatol       Date:  2014-12-24

6.  Melanoma screening with cellular phones.

Authors:  Cesare Massone; Rainer Hofmann-Wellenhof; Verena Ahlgrimm-Siess; Gerald Gabler; Christoph Ebner; H Peter Soyer
Journal:  PLoS One       Date:  2007-05-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.